Nephrol Dial Transplant (2001) 16: 302-306
© 2001 European Renal Association-European Dialysis and Transplant Association
Impaired endothelium-dependent vasodilatation in renal failure in humans
Department of Medical Sciences, University Hospital, Uppsala, Sweden
Background. The main causes of death in patients with chronic renal failure (CRF) are cardiovascular complications. The aim of the present study was to compare endothelium-dependent vasodilatation (EDV) in patients with chronic renal failure with a control population controlling for hypertension, diabetes mellitus and hypercholesterolaemia.
Methods. Fifty-six patients with moderate CRF (mean creatinine clearance 29.4 ml/min/1.73 m2) underwent evaluation of EDV and endothelium-independent vasodilatation (EIDV) by means of forearm blood flow (FBF) measurements with venous occlusion plethysmography during local intra-arterial infusions of methacholine (Mch, 2 and 4 µg/min evaluating EDV) and sodium nitroprusside (SNP, 5 and 10 µg/min evaluating EIDV). Fifty-six control subjects without renal impairment underwent the same investigation.
Results. Infusion of Mch increased FBF significantly less in patients with renal failure than in controls (198 vs 374%, P<0.001), whereas no significant difference was seen regarding the vasodilatation induced by SNP (278 vs 269%). The differences in EDV between the groups were still significant after controlling for hypertension, blood glucose, and serum cholesterol in multiple regression analysis (P<0.001). EDV was related to serum creatinine (r=-0.37, P<0.01), creatinine clearance (r=0.45, P<0.005) and to serum triglyceride levels (r=-0.29, P<0.005) in the CRF group.
Conclusions. Patients with moderate CRF have an impaired EDV even after correction for traditional cardiovascular risk factors and this impairment is related to the degree of renal failure.
Keywords: chronic renal failure; endothelium; renal function; triglycerides; vasodilatation
Correspondence and offprint requests to: Margus Annuk MD, Department of Medical Sciences, Renal Unit, University Hospital, entr 40, SE-751 85 Uppsala, Sweden.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  S. S. Billecke, L. G. D'Alecy, R. Platel, S. E. Whitesall, K. A. Jamerson, R. L. Perlman, and C. A. Gadegbeku Blood content of asymmetric dimethylarginine: new insights into its dysregulation in renal disease Nephrol. Dial. Transplant., February 1, 2009; 24(2): 489 - 496. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Linden, W. Cai, J. C. He, C. Xue, Z. Li, J. Winston, H. Vlassara, and J. Uribarri Endothelial Dysfunction in Patients with Chronic Kidney Disease Results from Advanced Glycation End Products (AGE)-Mediated Inhibition of Endothelial Nitric Oxide Synthase through RAGE Activation Clin. J. Am. Soc. Nephrol., May 1, 2008; 3(3): 691 - 698. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Zoccali Endothelial dysfunction in CKD: a new player in town? Nephrol. Dial. Transplant., March 1, 2008; 23(3): 783 - 785. [Full Text] [PDF]
|
|
|
|
|
|
J. Nogueira and M. Weir The Unique Character of Cardiovascular Disease in Chronic Kidney Disease and Its Implications for Treatment with Lipid-Lowering Drugs Clin. J. Am. Soc. Nephrol., July 1, 2007; 2(4): 766 - 785. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. S. Goligorsky Endothelial cell dysfunction: can't live with it, how to live without it Am J Physiol Renal Physiol, May 1, 2005; 288(5): F871 - F880. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V.-C. Wu, P.-R. Hsueh, W.-C. Lin, J.-W. Huang, H.-B. Tsai, Y.-M. Chen, K.-D. Wu, and The SARS Research Group of the National Taiwan Uni Acute renal failure in SARS patients: more than rhabdomyolysis Nephrol. Dial. Transplant., December 1, 2004; 19(12): 3180 - 3182. [Full Text] [PDF]
|
|
|
|
 |
|
 J. Stewart, A. Kohen, D. Brouder, F. Rahim, S. Adler, R. Garrick, and M. S. Goligorsky Noninvasive interrogation of microvasculature for signs of endothelial dysfunction in patients with chronic renal failure Am J Physiol Heart Circ Physiol, December 1, 2004; 287(6): H2687 - H2696. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Hrafnkelsdottir, P. Ottosson, T. Gudnason, O. Samuelsson, and S. Jern Impaired Endothelial Release of Tissue-Type Plasminogen Activator in Patients With Chronic Kidney Disease and Hypertension Hypertension, September 1, 2004; 44(3): 300 - 304. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A.D. Booth, D.R.W. Jayne, R.K. Kharbanda, C.M. McEniery, I.S. Mackenzie, J. Brown, and I.B. Wilkinson Infliximab Improves Endothelial Dysfunction in Systemic Vasculitis: A Model of Vascular Inflammation Circulation, April 13, 2004; 109(14): 1718 - 1723. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. T. Jurkovitz, J. L. Abramson, L. V. Vaccarino, W. S. Weintraub, and W. M. McClellan Association of High Serum Creatinine and Anemia Increases the Risk of Coronary Events: Results from the Prospective Community-Based Atherosclerosis Risk in Communities (ARIC) Study J. Am. Soc. Nephrol., November 1, 2003; 14(11): 2919 - 2925. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Annuk, B. Fellstrom, and L. Lind Cyclooxygenase inhibition improves endothelium-dependent vasodilatation in patients with chronic renal failure Nephrol. Dial. Transplant., December 1, 2002; 17(12): 2159 - 2163. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Rathaus and J. Bernheim Oxygen species in the microvascular environment: regulation of vascular tone and the development of hypertension Nephrol. Dial. Transplant., February 1, 2002; 17(2): 216 - 221. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Annuk, M. Zilmer, L. Lind, T. Linde, and B. Fellstrom Oxidative Stress and Endothelial Function in Chronic Renal Failure J. Am. Soc. Nephrol., December 1, 2001; 12(12): 2747 - 2752. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Stenvinkel Endothelial dysfunction and inflammation--is there a link? Nephrol. Dial. Transplant., October 1, 2001; 16(10): 1968 - 1971. [Full Text] [PDF]
|
|